Elevated STK1p After the Second-Cycle-Chemotherapy Associated with Failure Poor Survival in I-II Stage of NSCLCs- Three Cases Reports

Zhenxin Wang, Guoqing Zhang, Jin Li, Hongbo Ma, Ji Zhou, Ellen He, Sven Skog
2021 Clinics of Surgery  
1.1. Aims: Thymidine Kinase 1(TK1) is a precision protein molecular target for assessment of tumor proliferating rate. This investigation of 3 cases is whether the elevated STK1p after the 2-cycle -chemotherapy is associated with failure poor survival of clinical stage I-II in Non-Small-Cell Lung Carcinomas (NSCLCs). Main Methods: The 3 post-operative NSCLCs with clinical stage I-II were confirmed by pathology and followed by individual chemotherapy. The Serum Thymidine Kinase 1 protein (STK1p)
more » ... was measured using the ECL dot blot assay. Results: Although the 3 cases are of early clinical stage I-II, an increasing STK1p following by the second cycle of chemotherapy was observed. The elevated STK1p appeared 3-17 months early as compared the tumor metastasis by CT, and the Response Evaluation Criteria in Solid Tumors was evaluated as stable disease. The 3 patients died due to the failure poor survival. Significance: The post-radical resection following by 2 cycle-chemotherapy is important critical-point time to measure STK1p if the value is increasing or decline. The elevated STK1p values can predict an earlier risk of tumor metastasis process than imaging. It can supply a strong advance advice to adapt a new individual treatment for a better prognosis in the NSCLCs in routing clinical setting.
doi:10.47829/cos.2021.61002 fatcat:z4cytm6atvhbpndlziu6jze5f4